Head-to-head · WeighScore
Claya vs Rebody Health
The verdict
Rebody Health takes it — 67.7/100 to 62.8/100.
Rebody Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Rebody Health (rebodyhealth.com), operated by Compound Technologies Inc., is a transparent-pricing GLP-1 and wellness telehealth service that publishes prices up front.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Claya | Rebody Health |
|---|---|---|
| WeighScore | 62.8/100 | 67.7/100 |
| Grade | C | C |
| Scorecard rank | #267 | #162 |
| Semaglutide | $299/mo (compounded) | $200/mo (starting dose, compounded) |
| Tirzepatide | $299/mo (compounded) | $250/mo (starting dose, compounded) |
| Coverage | Coverage not published | 47 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Yes |
Graded #267 · C
Strengths
- Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
- Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
- Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
- Weight-loss money-back guarantee published on the homepage
- Free expedited shipping included in the monthly price
Where it loses points
- States-served list not disclosed — you must check at checkout
- LegitScript certification status not displayed
- Corporate legal entity not disclosed on the site or privacy policy
- Oral compounded tablets have weaker efficacy data than injectable semaglutide
- Intro pricing is higher at refill ($299), erasing the first-month advantage
Graded #162 · C
Strengths
- Publishes transparent, dose-based pricing up front on a public pricing page, so you can see costs without signing up
- Offers compounded semaglutide and tirzepatide as both weekly injections and daily oral 'melt' tablets
- Also carries brand-name Wegovy and Zepbound for patients who want FDA-approved products
- Clear plan-term vs dose-tier structure; the refill price is shown before each shipment, plus $50 off the first month
- Names its operating company (Compound Technologies Inc.) and references LegitScript approval
Where it loses points
- Individual compounding pharmacies are not named on the marketing site
- Not available in Massachusetts, Rhode Island, or Vermont
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
- Dose-scaled pricing means the monthly cost can rise as your prescribed dose increases
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.